🇺🇸 flucinolone acetonide in United States

FDA authorised flucinolone acetonide on 8 April 2005

Marketing authorisations

FDA — authorised 8 April 2005

  • Application: NDA021737
  • Marketing authorisation holder: BAUSCH AND LOMB
  • Local brand name: RETISERT
  • Indication: IMPLANT — INTRAVITREAL
  • Status: approved

Read official source →

FDA

  • Status: approved

flucinolone acetonide in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is flucinolone acetonide approved in United States?

Yes. FDA authorised it on 8 April 2005; FDA has authorised it.

Who is the marketing authorisation holder for flucinolone acetonide in United States?

BAUSCH AND LOMB holds the US marketing authorisation.